$APPY (Venaxis, Inc.)

$APPY {{ '2016-09-14T08:07:10+0000' | timeago}} • Announcement

$APPY said it has acquired Boulder, CO-based BiOptix Diagnostics. BiOptix has developed a proprietary Enhanced Surface Plasmon Resonance technology for detection of molecular interactions. $APPY acquired as of Sept. 12 about 98% of voting shares of BiOptix for about 14% of $APPY post-deal outstanding shares. Terms of acquisition were not disclosed.

$MCK {{ '2017-07-21T16:07:44+0000' | timeago}} • Announcement

Biologics, a unit of healthcare technology firm $MCK, said it will join the limited distribution network of $PBYI to promote the latter’s kinase inhibitor Nerlynx. The formulation is indicated for treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer.

$VRX {{ '2017-07-17T14:04:54+0000' | timeago}} • Announcement

$VRX has entered into an agreement to sell its Obagi Medical Products business for $190MM in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. The transaction is expected to close in second half of 2017. $VRX intends to use the proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility.

$NEOG {{ '2017-07-17T13:08:38+0000' | timeago}} • Announcement

$NEOG appointed John Adent as CEO, effective immediately. James Herbert, the company’s founder and former CEO, will remain as executive chairman and work closely with Adent in the transition of responsibilities.

$VRTX {{ '2017-07-13T12:31:35+0000' | timeago}} • Announcement

$VRTX announced that the Italian Medicines Agency has agreed to reimburse ORKAMBI (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older who have two copies of the F508del mutation. Effective immediately, hundreds of eligible patients in Italy will have access to this medicine.

$NEOG {{ '2017-07-10T15:50:19+0000' | timeago}} • Announcement

$NEOG developed an innovative test that detects Listeria in environmental samples in under 60 minutes, without the need to enrich samples. The test is also under review for AOAC Performance Tested certification to further validate its accuracy.

$VRX {{ '2017-07-10T13:27:06+0000' | timeago}} • Announcement

$VRX pays down $811MM of senior secured term loans using the net proceeds of the sale of Dendreon Pharmaceuticals LLC. The company has now reduced its debt by more than $4.3Bil since the end of 1Q16. $VRX still expects to pay down $5Bil in debt from divestiture proceeds and free cash flow within 18 months of August 2016.

$VIVO {{ '2017-06-30T16:33:27+0000' | timeago}} • Announcement

$VIVO provided clarifying comments regarding a June 29, 2017 letter from a group of U.S. Senators to the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). The letter pertains to venous blood lead testing performed on the systems produced by $VIVO's subsidiary Magellan Diagnostics.

$WBA {{ '2017-06-29T14:01:47+0000' | timeago}} • Announcement

$WBA agreed to buy 2,186 stores, three distribution centers and related inventory from $RAD. $WBA expects the new transaction to be modestly accretive to its adjusted EPS in the first full year after the initial closing of the new transaction, and expects to realize synergies from the new transaction in excess of $400MM.

$WBA {{ '2017-06-29T14:01:00+0000' | timeago}} • Announcement

$WBA agreed to buy 2,186 stores, three distribution centers and related inventory from $RAD. This new agreement replaces the previous merger agreement with Rite Aid, announced in October 2015 and amended in January 2017. The initial closing of the new transaction is expected to occur within the next six months.

$WBA {{ '2017-06-29T14:00:00+0000' | timeago}} • Announcement

$WBA agreed to buy 2,186 stores, three distribution centers and related inventory from $RAD. The consideration for the transaction will be $5.175Bil in cash, the assumption by $WBA of the related real estate leases and the grant of an option to $RAD to become a member of $WBA's group purchasing organization, Walgreens Boots Alliance Development.

$WBA {{ '2017-06-29T13:35:36+0000' | timeago}} • Webcast

$WBA said that on the $RAD agreement, while the company is assuming a real-estate obligation, it is not assuming any debt. Additionally, $WBA is expecting the deal to give significant cash tax benefit, as it tax amortizes the intangible assets it acquires from $RAD.

$RAD {{ '2017-06-29T12:19:47+0000' | timeago}} • Announcement

In 1Q18, $RAD opened one store, relocated four, remodeled 67 and expanded one store, bringing the total number of wellness stores chainwide to 2,482. The company closed 14 stores, resulting in a total store count of 4,523 at the end of the first quarter.

$RAD {{ '2017-06-29T12:18:00+0000' | timeago}} • Announcement

Drugstore chain $RAD posted revenue of $7.8Bil in 1Q18, a decrease of 4.9%, as same store sales slid 3.9% YoY. Net loss widened to $75.3MM or $0.07 per share, compared to last year’s $4.6MM or $0.00 per share, hurt by lower pharmacy gross profit. Adjusted EBITDA was $192.6MM compared to $286MM in the year-over period.

$RAD {{ '2017-06-29T12:09:28+0000' | timeago}} • Announcement

$RAD and $WBA announced that the latter will not buy the former as initially announced. Instead of the previously announced deal that was severely scrutinized by the Federal Trade Commission, $WBA will instead buy 2,186 Rite Aid Stores and Related Assets for $5.17Bil. Rite Aid will receive $325MM from $WBA as termination fee.

$WBA {{ '2017-06-29T11:32:22+0000' | timeago}} • Announcement

$WBA, which reached an agreement with $RAD worth $5.17Bil today, reported a modest 5% increase in earnings for 3Q17 upon strategic partnerships that brought more patients to its pharmacies. Both sales and earnings inched up, with sales scaling up 2.1% to $30.1Bil, while earnings rose to $1,162MM. Adjusted earnings spiked 12.7% to $1.33 per share.

$NEOG {{ '2017-06-19T16:35:46+0000' | timeago}} • Announcement

$NEOG announced the availability of next generation sequencing services for the food industry, which will enable food companies to accurately identify all bacteria in a sample in a single genomic test. The new NeoSeek tests will be performed at $NEOG's GeneSeek facilities in Lincoln, Neb.

$MYGN {{ '2017-06-15T12:42:35+0000' | timeago}} • Announcement

Crescendo Bioscience, a subsidiary of $MYGN, said new data from a meta-analysis of clinical studies and a registry demonstrating the ability of the Vectra DA test to predict joint damage were presented at the European League Against Rheumatism (EULAR) meeting in Madrid, Spain.

$VRTX {{ '2017-06-09T09:55:40+0000' | timeago}} • Announcement

$VRTX shareholders have elected Alan M Garber as an independent member of its board of directors. Garber is provost of Harvard University, the Mallinckrodt Professor of Health Care Policy at Harvard Medical School, a Professor of Economics in the Faculty of Arts and Sciences and a Professor of Public Policy in the Harvard Kennedy School of Govt.

$MYGN {{ '2017-06-08T11:43:30+0000' | timeago}} • Announcement

Crescendo Bioscience, a subsidiary of $MYGN will present new data on the use of Vectra DA test at the meeting of the European League Against Rheumatism to be held from June 14 to 17, 2017.  Vectra DA is the only multi-biomarker blood test proven to measure disease activity and predict joint damage progression in patients with rheumatoid arthritis.

$FRED {{ '2017-06-06T12:57:05+0000' | timeago}} • Webcast

$FRED is collaboratively working with $WBA, $RAD and Federal Trade Commission to obtain the FTC's approval of the divestiture of certain Rite Aid assets to Fred's Pharmacy in connection with Walgreen's pending acquisition of Rite Aid. The company is committed to purchasing additional assets, including up to 1,200 Rite Aid stores.

Recent Transcripts

TRIB (Trinity Biotech plc)
Thursday, July 20 2017 - 3:00pm
NEOG (Neogen Corp.)
Tuesday, July 18 2017 - 3:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PTX (Pernix Therapeutics Holdings, Inc.)
Monday, May 15 2017 - 8:30pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
MYGN (Myriad Genetics, Inc.)
Tuesday, May 2 2017 - 8:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
TRIB (Trinity Biotech plc)
Thursday, April 27 2017 - 3:00pm
QDEL (Quidel Corp.)
Monday, April 24 2017 - 9:00pm
VRML (Vermillion, Inc.)
Wednesday, March 29 2017 - 8:30pm
PTX (Pernix Therapeutics Holdings, Inc.)
Tuesday, March 28 2017 - 8:30pm
NEOG (Neogen Corp.)
Tuesday, March 21 2017 - 3:00pm
TRIB (Trinity Biotech plc)
Tuesday, March 14 2017 - 3:00pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, February 28 2017 - 10:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, February 28 2017 - 1:00pm
IMMU (Immunomedics Inc.)
Friday, February 10 2017 - 1:00pm

AlphaGraphics you may like